Novel Biomarker for Diagnosis and Treatment of Chronic Lung Diseases

Technology #ua16-096

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Pasano Bojang
Sr. Research Associate, Medicine
Elsa Reyes Reyes
Research Assistant Professor, Medicine
Kenneth Ramos
Associate VP, Precision Health Sciences, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Novel Biomarker for Diagnosis and Treatment of Chronic Lung Diseases

 

Invention: This technology is the discovery and insight of Long Interspersed Element (LINE-1) biology and transcriptional control for detection and treatment of lung related diseases. The activation of LINE-1 mediates the coding of ORF-1 and ORF-2 proteins, which are involved in the early steps of the oncogenesis process.

 

Background: Transforming growth factor beta 1 (TGFb1) is necessary to mediate the oncogenic phenotype induced by B[a]P activation of LINE-1. B(a)P is an environmental carcinogen. ORF-1 protein (translated from LINE-1 mRNA) is correlated with a pre-oncogenic phenotype in smokers with COPD. Products that inhibit TGFb1 and LINE-1 will improve cancers and diseases where LINE-1 activation is the cause of the dysregulation.

 

Applications:

  • Platforms for the use of LINE-1 in treatment and diagnosis of diseases
  • Diagnostic biomarkers for COPD and lung cancer
  • Immunoassays for ORF1 in blood, liquid biopsy, fresh and fixed tissue 
  • Algorithms enabling clinical decision making with ORF-1 and ORF-2, or LINE-1 sequence information
  • DNA sequence-based decision rules for genetic material obtained from blood, liquid biopsy, fixed tissue
  • DNA probes (in situ hybridization, chromosome paints) for LINE1 polymorphs from genetic material obtained from blood, liquid biopsy, and fixed tissue
  • Expression assays of LINE-1 (in situ hybridization, microarrays, RNAseq, RT-PCR in blood, liquid biopsy, fresh and fixed tissue)
  • Natural products with medicinal properties
  • Newly discovered drugs designed to inhibit aberrant LINE-1 activation

 

Advantages:

  • May meet the unmet need for the detection and treatment of lung cancer and other chronic lung diseases
  • Sinks and traps decoy receptors and binding proteins that sequester TGFb1 (activin receptor-like kinases)
  • Can utilize TGF beta inhibitors to inhibit the expression of LINE-1 for treatment of COPD and other lung related diseases
  • Provides an expansive platform

 

Licensing Manager: 

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695